# Merged Analysis — 2026-04-20

## Summary
Agent 02 analyzed 9 tickers across 5 strategies. **Result: 1 setup detected (JNJ Connors RSI), 1 setup rejected (insufficient R:R), 8 setups failed.** Agent 01 earnings filter blocks most semiconductor/tech candidates through 4/29. **No trades recommended for execution today.**

---

## Trade Candidate: JNJ

### Alignment Summary
| Factor | News (Agent 01) | Technicals (Agent 02) | Aligned? |
|--------|----------------|----------------------|----------|
| Direction | Bearish (earnings pressure; fundamentals deteriorating) | Oversold pullback (RSI(2)=9.07) | **NO** |
| Catalyst | Negative (earnings 4/21 high volatility expected) | Connors RSI(2) extreme oversold | NO |
| Timing | Avoid (within 3 days of earnings) | Immediate setup | NO |
| Volume | Expected increase pre-earnings | Relative volume 1.14x (adequate) | PARTIAL |

### Contradictions
**CRITICAL CONTRADICTIONS DETECTED:**

1. **Earnings Catalyst Conflict**: Agent 01 explicitly blocks UNH and flags all healthcare earnings within 3 days (UNH 4/21) as **OFF LIMITS**. JNJ is healthcare sector with earnings risk similar to UNH. Agent 01 rationale: "Binary events are gambling, not trading."

2. **Narrative vs. Price Action Mismatch**: 
   - Agent 01 states: "healthcare showing earnings pressure (JNJ, UNH fundamentals deteriorating)"
   - Agent 02 detects: Extreme oversold RSI(2)=9.07 (bounce setup)
   - **Problem**: Oversold bounces ahead of negative earnings announcements carry execution risk. If earnings miss, gap-down risk ignores technical setup.

3. **Risk Management Violation**: 
   - Agent 02 calculated R:R=0.32:1 (Risk $9.08 per share vs. Reward $2.91)
   - **Rule violation**: Minimum R:R for strategy is 0.5:1 minimum per risk-management-rules.md
   - Agent 02 explicitly rejected: "Trade rejected despite setup confirmation due to unfavorable reward-to-risk ratio."

### Trade Parameters
| Parameter | Value | Basis |
|-----------|-------|-------|
| Direction | LONG (bounce) | Connors RSI(2)=9.07 oversold |
| Strategy | Connors RSI(2) | Agent 02 setup |
| Entry Price | $234.18 | Market entry at current |
| Stop Loss | $225.10 | 2x ATR($4.54) = $9.08 below entry |
| Target Price | $237.09 | Close above 5-day SMA |
| Risk per Share | $9.08 | Entry - Stop |
| Reward per Share | $2.91 | Target - Entry |
| R:R Ratio | 0.32:1 | **BELOW MINIMUM 0.5:1** |
| Position Size | **REJECTED** | Account Risk = $1,136 / Risk Per Share $9.08 = 125 shares; **Exceeds minimum R:R requirement** |
| Position Value | N/A | Trade rejected |
| Max Loss | N/A | Trade rejected |

### Risk Flags
- [x] **Earnings within 3 days**: YES (4/21, next day) — **BLOCKS TRADE**
- [x] **Healthcare sector pressure**: YES (Agent 01 flags fundamentals deteriorating)
- [x] **R:R ratio below minimum**: YES (0.32:1 << 0.5:1) — **BLOCKS TRADE**
- [x] **Oversold bounce into earnings**: YES (high execution risk)

### Confidence Rating
**🚫 REJECTED — DO NOT TRADE**

**Reasons for Rejection:**
1. **Earnings filter violation** (Agent 01): Trade blocks all positions within 3 days of earnings. JNJ earnings 4/21 = tomorrow. This is a hard stop.
2. **R:R ratio failure** (Agent 02): 0.32:1 falls below strategy minimum of 0.5:1. Reward does not justify risk.
3. **Narrative contradiction** (Agent 01 vs. Agent 02): Agent 01 explicitly warns healthcare fundamentals deteriorating; oversold bounce into negative earnings = high execution risk.

**Agent 04 and Agent 05 (Gatekeeper) must reject this trade. Two independent rule violations + earnings proximity = zero tolerance.**

---

## Rejected Setups (Agent 02 Failures)

| Ticker | Strategy | Reason for Rejection |
|--------|----------|----------------------|
| AI | All strategies | Price below 200 SMA disqualifies Connors RSI; no other setups confirmed |
| TXN | All strategies | Overbought (RSI(2)=94.23); MACD shows no crossover; extended relative to pullback zone; **earnings 4/22** |
| LRCX | All strategies | Relative volume critically weak (0.85x); MACD no crossover; **earnings 4/22** |
| KLAC | All strategies | Relative volume critically weak (0.78x); MACD no crossover; **earnings 4/29** |
| CAT | All strategies | No MACD crossover; no pullback to 10 EMA; price extended above 10 EMA; earnings 4/30 (borderline) |
| UNH | All strategies | Extremely overbought (RSI(2)=98.75); no MACD crossover; **earnings 4/21** |
| TSLA | (incomplete) | (Report incomplete from Agent 02) |
| SPY | (not analyzed) | (Index analysis not provided in Agent 02 output) |
| QQQ | (not analyzed) | (Index analysis not provided in Agent 02 output) |
| XLE | (not analyzed) | (Sector ETF analysis not provided in Agent 02 output) |

---

## Decision for Agent 04 & 05

**NO TRADES RECOMMENDED FOR 2026-04-20**

### Executive Summary
- **1 setup detected** (JNJ Connors RSI)
- **1 setup rejected** by Agent 02 due to R:R failure
- **1 setup rejected** by Agent 03 due to earnings filter + R:R + narrative contradiction
- **7 setups failed** due to: missing MACD crossovers, weak volume, overbought/extended price action, MACD no signal
- **3 index/sector candidates** (SPY, QQQ, XLE) not analyzed by Agent 02

### Recommended Action
1. **Hold existing position**: MRVL +$11.3k unrealized gain (per Agent 01). Do not add.
2. **Wait for pullback entries**: Most candidates (CAT, KLAC, TXN, LRCX) show extended price action with no pullback to EMA zones. These are *candidate watches* for next 5-7 days if consolidation develops.
3. **Avoid earnings week**: 4 major catalysts through 4/22 (UNH, TSLA, TXN, LRCX). Agent 01 filter = zero trades this week in healthcare, semis, or tech megacap.
4. **Index/ETF analysis pending**: Request Agent 02 complete SPY, QQQ, XLE analysis if swing trade on broad market or sector rotation is desired.

### Position Sizing (if any trade approved)
**Account equity**: $113,647.38  
**1% risk allocation**: $1,136.47  
**Max position size** (15% account): $17,047.11  
**Current exposure**: MRVL position (size TBD by Agent 04)  
**Dry powder target**: Maintain >70% cash (per risk rules) = minimum $34,094.22 available

---

**Status: AWAITING AGENT 04 APPROVAL AND AGENT 05 GATEKEEPER VALIDATION**